EI
ENTA icon

EAM Investors’s Enanta Pharmaceuticals ENTA Stock Holding History

EAM Investors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,952
Closed -$517K – 308
2026
Q1 		$517K Hold
40,952
– – 0.06% 262
2025
Q4 		$646K Buy
+40,952
New +$520K 0.07% 245
2022
Q1 		– Sell
-30,839
Closed -$2.31M – 313
2021
Q4 		$2.31M Buy
+30,839
New +$2.42M 0.38% 89
2018
Q3 		– Sell
-6,275
Closed -$727K – 321
2018
Q2 		$727K Sell
6,275
-3,863
-38% -$385K 0.11% 251
2018
Q1 		$820K Buy
+10,138
New +$780K 0.14% 222
2015
Q1 		– Sell
-74,915
Closed -$3.81M – 349
2014
Q4 		$3.81M Buy
74,915
+12,147
+19% +$544K 0.53% 35
2014
Q3 		$2.48M Sell
62,768
-1,786
-3% -$71.2K 0.5% 39
2014
Q2 		$2.78M Sell
64,554
-1,292
-2% -$49.3K 0.53% 28
2014
Q1 		$2.63M Sell
65,846
-1,862
-3% -$67.6K 0.47% 45
2013
Q4 		$1.85M Buy
+67,708
New +$1.64M 0.33% 101

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EAM Investors's ENTA Position: Q2 2026 in Review

EAM Investors sold out of Enanta Pharmaceuticals (ENTA) in Q2 2026, closing a stake of 40,952 shares — an estimated $517K sold.

EAM Investors first reported a position in ENTA in Q4 2013 and held it in 10 quarters. The position peaked at $3.81M in Q4 2014. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • EAM Investors reported no remaining Enanta Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • EAM Investors sold 40,952 Enanta Pharmaceuticals shares in Q2 2026, an estimated $517K.
  • EAM Investors first reported a position in Enanta Pharmaceuticals in Q4 2013 and held it in 10 quarters.
  • EAM Investors's Enanta Pharmaceuticals position peaked at $3.81M in Q4 2014.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.